Literature DB >> 11556820

Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes.

M Maccarrone1, L De Petrocellis, M Bari, F Fezza, S Salvati, V Di Marzo, A Finazzi-Agrò.   

Abstract

Lipopolysaccharide (LPS) increases the levels of the endogenous cannabinoid anandamide (N-arachidonoylethanolamine, AEA) in rat macrophages, but the mechanism responsible for this effect has not been elucidated. Here we demonstrate that LPS enhances the levels of AEA (fourfold over controls) also in human lymphocytes. We show that in these cells LPS inhibits the activity of the AEA-degrading enzyme fatty acid amide hydrolase (FAAH), by downregulating the gene expression at transcriptional level. Lymphocytes have also a specific AEA transporter and a functional CB1 cannabinoid receptor, which were not modulated by LPS. The effect of this endotoxin on FAAH was not mediated by AEA-induced activation of cannabinoid receptors. Conversely, the stimulatory action of LPS on AEA levels might be due to inhibition of FAAH, as suggested by the observation that an increase of AEA amounts was also induced by an irreversible FAAH inhibitor. These results suggest that lymphocytes take part in regulating the peripheral endocannabinoid system and endocannabinoid homeostasis. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556820     DOI: 10.1006/abbi.2001.2500

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  52 in total

Review 1.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

Review 2.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

Review 3.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 4.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 5.  Endocannabinoids and the haematological system.

Authors:  M D Randall
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

Review 6.  Endocannabinoids and immune regulation.

Authors:  Rupal Pandey; Khalida Mousawy; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Pharmacol Res       Date:  2009-04-07       Impact factor: 7.658

7.  Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice.

Authors:  M Bashashati; M A Storr; S P Nikas; J T Wood; G Godlewski; J Liu; W Ho; C M Keenan; H Zhang; S O Alapafuja; B F Cravatt; B Lutz; K Mackie; G Kunos; K D Patel; A Makriyannis; J S Davison; K A Sharkey
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 8.  Endocannabinoids and cardiac contractile function: pathophysiological implications.

Authors:  Sándor Bátkai; Pál Pacher
Journal:  Pharmacol Res       Date:  2009-08       Impact factor: 7.658

9.  Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders.

Authors:  Dario Siniscalco; Anna Sapone; Catia Giordano; Alessandra Cirillo; Laura de Magistris; Francesco Rossi; Alessio Fasano; James Jeffrey Bradstreet; Sabatino Maione; Nicola Antonucci
Journal:  J Autism Dev Disord       Date:  2013-11

Review 10.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.